SEATTLE, Aug. 10, 2020 /PRNewswire/ -- AGC Biologics,
a global biopharmaceutical Contract Development and Manufacturing
Organization (CDMO), announced it has expanded its partnership with
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases. AGC Biologics is currently preparing to manufacture
Matrix-M™, the adjuvant component of Novavax' coronavirus vaccine,
NVX-CoV2373, from its facility in Copenhagen. AGC Biologics will now expand
supply of Matrix-M adjuvant for the vaccine from its facility in
Seattle to ensure supply for
the United States.
NVX-CoV2373 is a stable, prefusion protein made using Novavax'
proprietary nanoparticle technology. AGC Biologics will optimize
process development for scaled-up production of Matrix-M to enable
Novavax' ability to deliver significant worldwide supply in 2020
"We are extremely proud that Novavax has asked us to expand our
production of its coronavirus vaccine, NVX-CoV2373, in Seattle," says AGC Biologics' CBO Mark Womack.
"This enables us to further support Novavax' need to move this
vaccine forward with extraordinary urgency."
"We are pleased to expand our partnership with AGC Biologics
into the United States. They have
established themselves as a critical partner in our supply chain of
adjuvant for NVX-CoV2373, and we are grateful for their high level
of commitment and flexibility in meeting the urgent demands of this
project," says Timothy J. Hahn, SVP,
Process Technology at Novavax.
"We are very happy to have the opportunity to serve Novavax at
another facility in our global network and to be able to do even
more in the fight against the coronavirus pandemic," says AGC
Biologics' CEO Patricio Massera.
AGC Biologics' global network spans three continents, with
cGMP-compliant facilities in Seattle,
Denmark; Heidelberg, Germany; Milan,
Italy and Chiba, Japan.
Their best in class services include development and manufacturing
of mammalian and microbial-based therapeutic proteins, plasmid DNA
(pDNA), viral vectors and genetically engineered cells.
Novavax, Inc. (Nasdaq:NVAX) is a
late-stage biotechnology company that promotes improved health
globally through the discovery, development, and commercialization
of innovative vaccines to prevent serious infectious diseases.
Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine
candidate against SARS-CoV-2, the virus that causes COVID-19.
NVX-CoV2373 was generally well-tolerated and elicited robust
antibody responses numerically superior to that seen in human
convalescent sera in its Phase 1 data of the Phase 1/2 clinical
trial. NanoFlu™, its quadrivalent influenza nanoparticle vaccine,
met all primary objectives in its pivotal Phase 3 clinical trial in
older adults. Both vaccine candidates incorporate Novavax'
proprietary saponin-based Matrix-M™ adjuvant in order to enhance
the immune response and stimulate high levels of neutralizing
antibodies. Novavax is a leading innovator of recombinant vaccines;
its proprietary recombinant technology platform combines the power
and speed of genetic engineering to efficiently produce highly
immunogenic nanoparticles in order to address urgent global health
needs. Learn more at www.novavax.com.
About AGC Biologics:
AGC Biologics is a leading global
Biopharmaceutical Contract Development and Manufacturing
Organization (CDMO) with a strong commitment to deliver the highest
standard of service to clients and partners. The company currently
employs more than 1,300 employees worldwide. AGC Biologics has
decades of experience in CDMO development and manufacturing,
including providing commercial market supply with FDA, PDMA and EMA
AGC Biologics offers deep industry expertise and unique
customized services. Integrated service offerings include cell line
development, bioprocess development, formulation, analytical
testing, antibody drug development and conjugation, cell banking
and storage and protein expression, including the proprietary
CHEF1® Expression System for mammalian production.
AGC Biologics is committed to continuous innovation and offers
the technical creativity to solve clients' most complex challenges,
including specialization in fast-track projects for orphan drugs
and rare diseases. Learn more at www.agcbio.com.
View original content to download
SOURCE AGC Biologics